OBJECTIVE： To systematically review the therapeutic efficacy and safety of modified Taohong siwu decoction in adjuvant therapy of traumatic fracture， and to provide evidence-based reference in clinic. METHODS： Retrieved from CJFD， CBM， Wanfang database and PubMed， related studies about fracture restitution combined with modified Taohong siwu decoction （trial group） vs. fracture restitution alone （control group） in the treatment of traumatic fracture were collected. Meta-analysis was conducted by using Rev Man 5.3 statistical software after data extraction and quality evaluation according to Cochrane systematic review. RESULTS： A total of 6 RCTs and 3 clinical control trials were included， involving 929 patients. Meta-analysis showed that clinical total response rate [RR＝1.35，95％Cl（1.24，1.47），P＜0.001] and the incidence of gastrointestinal ADR [RR＝5.59，95％Cl（1.30，24.14），P＝0.02] in trial group were significantly higher than control group； symptom and sign score [MD＝－5.50，95％Cl（－6.45，－4.54），P＜0.001]， erythrocyte sedimentation [MD＝－13.78，95％Cl（－15.97，－11.60），P＜0.01]， whole blood viscosity [MD＝－1.03，95％Cl（－1.11，－0.95），P＜0.001]， plasma viscosity [MD＝－0.24，95％Cl（－0.27，－0.21），P＜0.01]， hematocrit [MD＝－12.12，95％Cl（－13.37，－10.86），P＜0.01] and erythrocyte electrophoresis time [MD＝－7.12，95％Cl（－7.88，－6.35），P＜0.01] of trial group were significantly lower than those of control group， with statistical significance. CONCLUSIONS： For adjunctive therapy of traumatic fracture， modified Taohong siwu decoction can improve clinical efficacy， reduce the inflammatory reaction， improve blood rheology but aggravate gastrointestinal reaction.